DOCSLIB.ORG

PASS Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PASS Information PASS Information Document title Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury Protocol version identifier 2.1 Date of last version of 22 July 2015 protocol EU PAS Register number Will be registered following European Medicines Agency endorsement and prior to start of data collection Active substance (ATC Agomelatine (N06AX22) code) Medicinal product Valdoxan®, Thymanax® Product reference EU/1/08/499/001-008 (Valdoxan®) EU/1/08/498/001-008 (Thymanax®) Procedure number EMEA/H/C/915 ( Valdoxan) EMEA/H/C/916 (Thymanax) Marketing authorisation Les Laboratoires Servier holder(s) Joint PASS No Research question and The objective is to compare the risk of hospitalisation for acute objectives liver injury in patients initiating treatment with agomelatine and other antidepressants with the risk in patients initiating treatment with citalopram Country(-ies) of study Spain, Germany, Denmark, and Sweden Author Manel Pladevall, MD, MS RTI Health Solutions Trav. Gracia 56 Atico 1 08006 Barcelona, Spain Telephone: +34.93.241.7768 Fax: +34.93.414.2610 E-mail: [email protected] Marketing authorisation Les Laboratoires Servier holder(s) 50, rue Carnot 92284 Suresnes France PASS of Agomelatine and the Risk of Hospitalisation for Liver Injury MAH contact person Christèle Percheron, Regulatory Affairs Product Manager, Registrations Europe Les Laboratoires Servier/ Science Union - 50, rue Carnot - 92284 Suresnes cedex - France E-mail: [email protected] CONFIDENTIAL CONFIDENTIAL 2 / 112 PASS of Agomelatine and the Risk of Hospitalisation for Liver Injury Approval Page: Scientific Advisers Project Title: Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury IRIS Protocol ID Number: CLE-20098-94 Effective Date: Authors Manel Pladevall, MD, MS; Cristina Rebordosa, MD, PhD; Jordi Castellsague, MD, MPH; Susana Perez-Gutthann, MD, MPH, PhD; (RTI Health Solutions) Version: 2.1 Version Date: 22 July 2015 The following people have reviewed the protocol Prof. Bruno Falissard Professor in Public Health; Head of INSERM Research Unit U669 (Public Health and Mental Health); Child & Adolescent Psychiatrist Prof. Gabriel Perlemuter Head of the Department of Hepato-Gastroenterology and Nutrition Antoine-Beclere University Hospital - Univ. Paris-South INSERM U996 – Head of team 3 : Intestinal Microbiota, Macrophages and Liver Inflammation DHU Hépatinov Note: The final version of the protocol will be signed by a representative of each research partner: IACS, SIDIAP, BIPS GmbH, University of Southern Denmark (Institute of Public Health), and Karolinska Institutet CONFIDENTIAL 5 / 112 PASS of Agomelatine and the Risk of Hospitalisation for Liver Injury 1. TABLE OF CONTENTS 1. TABLE OF CONTENTS .................................................................................................... 6 2. LIST OF ABBREVIATIONS ........................................................................................... 12 3. RESPONSIBLE PARTIES .............................................................................................. 14 4. ABSTRACT ....................................................................................................................... 15 5. AMENDMENTS AND UPDATES .................................................................................. 17 6. MILESTONES AND TIMELINE ................................................................................... 22 7. RATIONALE AND BACKGROUND ............................................................................. 23 8. RESEARCH QUESTION AND OBJECTIVES ............................................................ 24 8.1. Specific Aims ................................................................................................................. 24 9. RESEARCH METHODS ................................................................................................. 24 9.1. Study Design .................................................................................................................. 24 9.2. Setting ............................................................................................................................. 26 9.2.1. Source Population ........................................................................................................ 26 9.2.2. Study Period ................................................................................................................. 26 9.2.3. Study Cohort ................................................................................................................ 26 9.2.3.1. Study Antidepressants ............................................................................................. 27 9.2.3.2. New Users ............................................................................................................... 28 9.2.3.3. Start Date ................................................................................................................. 28 9.2.3.4. Eligibility Criteria .................................................................................................... 28 9.2.3.5. Exclusion Criteria .................................................................................................... 28 9.2.3.6. Follow-up ................................................................................................................ 29 9.2.4. Nested Case-Control Study .......................................................................................... 29 9.2.4.1. Selection of Cases ................................................................................................... 29 9.2.4.2. Selection of Controls ............................................................................................... 29 9.2.4.3. Index Date ............................................................................................................... 30 9.3. Variables ......................................................................................................................... 30 9.3.1. Endpoint Definition and Ascertainment ...................................................................... 30 9.3.1.1. Endpoint Definition ................................................................................................. 31 9.3.1.1.1. Primary Endpoint (All Countries and Databases) ................................................. 32 9.3.1.1.2. Secondary Endpoint (Selected Databases) ............................................................ 32 9.3.1.1.3. Tertiary Endpoint (All Databases) ........................................................................ 33 9.3.1.1.4. Validation of Secondary and Tertiary Endpoints .................................................. 33 9.3.2. Exposure Assessment ................................................................................................... 35 9.3.2.1. Exposure and Time at Risk in the Cohort Study ..................................................... 35 9.3.2.2. Exposure and Time at Risk in the Nested Case-Control Study ............................... 36 9.3.2.3. Assessment of Dose and Duration ........................................................................... 37 9.3.3. Risk Factors and Confounding ..................................................................................... 38 CONFIDENTIAL 6 / 112 PASS of Agomelatine and the Risk of Hospitalisation for Liver Injury 9.3.3.1. Cohort Study ............................................................................................................ 39 9.3.3.2. Nested Case-Control Study ..................................................................................... 39 9.3.3.2.1. Age and Sex .......................................................................................................... 40 9.3.3.2.2. Socioeconomic Status ........................................................................................... 40 9.3.3.2.3. Liver Disease and Risk Factors ............................................................................. 40 9.3.3.2.3.1. Specifications for Risk Factors for Liver Injury ................................................. 40 9.3.3.2.4. Disease of the Biliary Tract or Pancreas ............................................................... 41 9.3.3.2.5. Pregnancy .............................................................................................................. 41 9.3.3.2.6. Severe Comorbidity .............................................................................................. 41 9.3.3.2.7. Concurrent Use of Other Hepatotoxic Drugs ........................................................ 42 9.3.3.2.8. Concurrent Use of Other Antidepressants ............................................................ 44 9.3.3.2.9. Indication for Treatment With Antidepressants and Other Mental and Behavioural Disorders ............................................................................................................... 44 9.3.3.2.10. Time Since First Antidepressant Prescription ....................................................... 45 9.3.3.2.11. Number of Liver Tests Performed ........................................................................ 45 9.3.3.2.12. Health Care Utilisation.......................................................................................... 46 9.4. Data Sources ..................................................................................................................
Load more

Recommended publications
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Gps' Drug Treatment for Depression by Patients' Educational Level
    RESEARCH GPs’ drug treatment for depression by patients’ educational level: registry- based study Anneli Borge Hansen, MD1,2*, Valborg Baste, MSc. Statistics, PhD1, Oystein Hetlevik, MD, PhD1,2, Inger Haukenes, MSc. Philosophy, PhD1,2, Tone Smith- Sivertsen, MD, PhD1,3, Sabine Ruths, MD, PhD1,2 1Research Unit for General Practice, NORCE Norwegian Research Centre, Bergen, Norway; 2Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; 3Division of Psychiatry, Haukeland University Hospital, Bergen, Norway Abstract Background: Antidepressant drugs are often prescribed in general practice. Evidence is conflicting on how patient education influences antidepressant treatment. Aim: To investigate the association between educational attainment and drug treatment in adult patients with a new depression diagnosis, and to what extent sex and age influence the association. Design & setting: A nationwide registry- based cohort study was undertaken in Norway from 2014– 2016. Method: The study comprised all residents of Norway born before 1996 and alive in 2015. Information was obtained on all new depression diagnoses in general practice in 2015 (primary care database) and data on all dispensed depression medication (Norwegian Prescription Database [NorPD]) 12 months after the date of diagnosis. Independent variables were education, sex, and age. Associations with drug treatment were estimated using a Cox proportional hazard model and performed separately for sex. *For correspondence: ahan@ Results: Out of 49 967 patients with new depression (61.6% women), 15 678 were dispensed drugs norceresearch. no (30.4% women, 33.0% men). Highly educated women were less likely to receive medication (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.88 to 0.98) than women with low education.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Belsomra®: a Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
    Pharmacy and Wellness Review Volume 7 Issue 1 Article 1 January 2016 Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia Shane Bogusz Ohio Northern University Steven Blake Ohio Northern University Michaela Wolford Ohio Northern University Victoria Cho Ohio Northern University Manoranjan D'Souza Ohio Northern University, [email protected] Follow this and additional works at: https://digitalcommons.onu.edu/paw_review Part of the Medical Pharmacology Commons, Nervous System Diseases Commons, Neurology Commons, and the Pharmaceutics and Drug Design Commons This Article is brought to you for free and open access by the ONU Journals and Publications at DigitalCommons@ONU. It has been accepted for inclusion in Pharmacy and Wellness Review by an authorized editor of DigitalCommons@ONU. For more information, please contact [email protected]. CNS Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia Shane Bogusz, Steven Blake, Michaela Wolford, Victoria Cho, Manoranjan D'Souza, M.D., Ph.D. Key Terms This knowledge-based activity is targeted for all pharmacists Belsomra®; Benzodiazepine; Dual Orexin Receptor Antago­ and is acceptable for 1.0 hour (0.1 CEU) of continuing nist; DORA, Insomnia, Insomnia Treatment, Orexin, education credit. This course requires completion Suvorexant of the program evaluation and at least a 70 percent grade on the program assessment questions. Introduction Insomnia refers to a disease state that involves persistent ACPE Universal Activity Number (UAN): 0048-0000-16-005-HOl-P difficulty falling asleep and/or frequent awakenings during sleep. Over 35 percent of the adult population exhibits one or To complete the continuing education program and receive more symptoms associated with insomnia, with 12 percent credit, please go to www.raabecollegeofpharmacy.org/PAW/.
    [Show full text]
  • Therapeutic Class Overview Sedative Hypnotics
    Therapeutic Class Overview Sedative Hypnotics Therapeutic Class • Overview/Summary: Insomnia is the most common sleep disorder in adulthood, affecting 33 to 69% of the population. It is estimated that five to ten percent of adults experience specific insomnia disorders.1,2 Insomnia is a disorder that results from a difficulty in initiating or maintaining sleep, waking too early, or sleep that is considered nonrestorative or poor quality.1-3 Furthermore, individuals with insomnia must also report at least one of the following types of daytime impairment as a result of the difficulties experienced with sleep: fatigue/malaise; impairment in memory, attention, or concentration; social or work-related dysfunction; poor school performance; irritability; day time sleepiness; loss of motivation, energy, or initiative; increased tendency for work or driving related accidents/errors; tension headaches; gastrointestinal symptoms; or concerns/worries about sleep. In individuals with insomnia, these complaints occur despite having sufficient opportunity and circumstances for sleep.1,2 According to the International Classification of Sleep Disorders, insomnia may be classified as one of the following: short-term insomnia, chronic insomnia or other insomnia (defined as patients who experience difficulty initiating or maintaining sleep but do not meet all of the criteria for either short-term or chronic insomnia).2 There are several classes of medications available for the management of insomnia.4-6 Doxepin (Silenor®) is a tricyclic antidepressant that
    [Show full text]
  • Association of Hormonal Contraception with Depression
    Supplementary Online Content Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiatry. Published online September 28, 2016. doi:10.1001/jamapsychiatry.2016.2387 eFigure 1. Women and Person-years Fulfilling Various Inclusion and Exclusion Criteria eFigure 2. Use of Different Types of Hormonal Contraceptives According to Age in Denmark 2013 eFigure 3. Use of Antidepressants in Users of Different Types of Hormonal Contraceptives Among Parous Women 15-34 Years Old eTable 1. Included Groups of Hormonal Contraceptives and Corresponding Anatomic Therapeutic Chemical (ATC) Codes eTable 2. Anatomic Therapeutic Chemical (ATC) Codes of the Included Antidepressants eTable 3. Relative Risk of First Use of Antidepressants in Users of Different Types of Hormonal Contraceptives Compared With Users of Combined Oral Contraceptives With Levonorgestrel eTable 4. Relative Risk of First Use of Antidepressants Compared With Never-Users of Hormonal Contraceptives eTable 5. Relative Risk of First Use of Antidepressants in Starters of Different Types of Hormonal Contraceptives: Adolescents 15-19 Years of Age and Women 20-30 Years of Age eTable 6. Overview of Articles on Hormonal Contraception and Depression eDiscussion. Comparison With Prior Studies This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eFigure 1. Women and Person-years Fulfilling Various Inclusion and Exclusion Criteria 1,359,499 all women living in Denmark 15–34 years 2000–2013 identified 243,012 Immigrated after 1995 1,887 Cancer 1,686 VTE-event 16,350 IVF-treatment 4,701 Psychiatric diagnoses 4,203 Depression diagnoses 27,063 Antidepressant use 1,061,997 women inclued in the study 6,832,938 person-years observation time after censoring 3,791,343 person-years of exposed to hormonal contraception © 2016 American Medical Association.
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Updates in Treating Major Depressive Disorder in the Elderly
    Evidence based Psychiatric Care Journal of the Italian Society of Psychiatry Updates in treating major depressive Società Italiana di Psichiatria disorder in the elderly: a systematic review Mario Amore1,2, Andrea Aguglia1,2, Gianluca Serafini1,2, Andrea Amerio1,2,3 1 Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy; 2 IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 3 Department of Psychiatry, Tufts University, Boston, USA Summary Among mental disorders, late life depression occurs in 7% of the general older population. Mario Amore An updated systematic review of randomized controlled trials (RCTs) on phar- macological and non-pharmacological treatment of major depressive disorder (MDD) in the elderly was conducted. Eight RCTs were carried out on 663 patients (mean age 70.99, SD 6.73). Vor- How to cite this article: Amore M, tioxetine (p = 0.897), saffron (η2 = 0.008) and tianeptine (p = 0.32) reduced Aguglia A, Serafini G, et al. Updates in depressive symptoms in MDD older adults, although no significant differences treating major depressive disorder in the in their efficacy were found when compared to sertraline and escitalopram, re- elderly: a systematic review. Evidence- spectively. Focusing on adverse events, in comparison with sertraline, vortiox- based Psychiatric Care 2021;7:23-31. https://doi.org/10.36180/2421-4469- etine did not show any significantly difference, while saffron was associated to 2021-5 less neurological disorders (RR 0.13, 95% CI 0.17-0.93, p = 0.02). Neurological (RR 0.46, 95% CI 0.3-0.71, p = 0.000) and gastrointestinal (RR 0.54, 95% CI Correspondence: 0.31-0.96, p = 0.04) disorders were also less common in patients under tianep- Mario Amore tine compared to escitalopram.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]